The University of Chicago Header Logo

Connection

Mary Rinella to Non-alcoholic Fatty Liver Disease

Back to Details
This is a "connection" page, showing publications Mary Rinella has written about Non-alcoholic Fatty Liver Disease.
Mary Rinella
Connection Strength
32.919
Non-alcoholic Fatty Liver Disease
  1. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clin Mol Hepatol. 2025 Jul; 31(3):753-770.
    View in: PubMed
    Score: 0.722
  2. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clin Gastroenterol Hepatol. 2024 Dec; 22(12):2367-2377.
    View in: PubMed
    Score: 0.687
  3. Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 Apr; 30(4):933-936.
    View in: PubMed
    Score: 0.673
  4. Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †. Hepatology. 2024 Feb 01; 79(2):E16-E17.
    View in: PubMed
    Score: 0.660
  5. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. J Hepatol. 2024 07; 81(1):e20-e21.
    View in: PubMed
    Score: 0.660
  6. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'. Ann Hepatol. 2024 Jul-Aug; 29(4):101178.
    View in: PubMed
    Score: 0.660
  7. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024 01; 65(1):100485.
    View in: PubMed
    Score: 0.659
  8. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation. Hepatology. 2025 Sep 01; 82(3):766-776.
    View in: PubMed
    Score: 0.659
  9. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Ann Med. 2023 12; 55(1):2211349.
    View in: PubMed
    Score: 0.658
  10. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024 Mar 01; 79(3):E93-E94.
    View in: PubMed
    Score: 0.656
  11. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024 05 01; 79(5):1212-1219.
    View in: PubMed
    Score: 0.655
  12. Pioneering the path to NASH biomarker approval. Nat Med. 2023 10; 29(10):2416-2417.
    View in: PubMed
    Score: 0.650
  13. Pegozafermin for NASH - A Sprint to Start a Marathon. N Engl J Med. 2023 09 14; 389(11):1044-1046.
    View in: PubMed
    Score: 0.648
  14. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 12 01; 78(6):1966-1986.
    View in: PubMed
    Score: 0.638
  15. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 12; 79(6):1542-1556.
    View in: PubMed
    Score: 0.638
  16. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024 Jan-Feb; 29(1):101133.
    View in: PubMed
    Score: 0.638
  17. Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. Hepatology. 2023 11 01; 78(5):E91-E92.
    View in: PubMed
    Score: 0.634
  18. Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology. 2023 12 01; 78(6):E103-E104.
    View in: PubMed
    Score: 0.634
  19. Recurrent NAFLD post-LT: Sisyphus' boulder or Proteus' parable? Liver Transpl. 2023 09 01; 29(9):917-918.
    View in: PubMed
    Score: 0.630
  20. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 05 01; 77(5):1797-1835.
    View in: PubMed
    Score: 0.626
  21. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. Clin Liver Dis. 2023 05; 27(2):251-273.
    View in: PubMed
    Score: 0.624
  22. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol. 2022 Jul 10; 22(1):335.
    View in: PubMed
    Score: 0.597
  23. Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023 02; 21(2):445-455.e2.
    View in: PubMed
    Score: 0.581
  24. Fatty Liver Disease: Diagnosis and Stratification. Annu Rev Med. 2022 01 27; 73:529-544.
    View in: PubMed
    Score: 0.572
  25. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
    View in: PubMed
    Score: 0.571
  26. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
    View in: PubMed
    Score: 0.570
  27. Non-alcoholic fatty liver disease. Lancet. 2021 06 05; 397(10290):2212-2224.
    View in: PubMed
    Score: 0.549
  28. The times they are a-changin' (for NAFLD as well). J Hepatol. 2020 12; 73(6):1307-1309.
    View in: PubMed
    Score: 0.525
  29. Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021 05; 19(5):1020-1029.e7.
    View in: PubMed
    Score: 0.519
  30. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol. 2020 07; 73(1):9-11.
    View in: PubMed
    Score: 0.513
  31. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 05; 158(7):1851-1864.
    View in: PubMed
    Score: 0.506
  32. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436.
    View in: PubMed
    Score: 0.485
  33. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 10; 71(4):823-833.
    View in: PubMed
    Score: 0.485
  34. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol. 2019 04; 114(4):579-590.
    View in: PubMed
    Score: 0.476
  35. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
    View in: PubMed
    Score: 0.466
  36. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
    View in: PubMed
    Score: 0.417
  37. Moderate Exercise for Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2016 08 01; 176(8):1083-4.
    View in: PubMed
    Score: 0.396
  38. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 07; 64(1):19-22.
    View in: PubMed
    Score: 0.387
  39. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci. 2016 May; 61(5):1387-97.
    View in: PubMed
    Score: 0.385
  40. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016 Apr; 13(4):196-205.
    View in: PubMed
    Score: 0.384
  41. Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?--In principle yes, in practice not yet. Hepatology. 2016 Mar; 63(3):688-90.
    View in: PubMed
    Score: 0.380
  42. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
    View in: PubMed
    Score: 0.365
  43. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015 Dec; 35(12):2575-83.
    View in: PubMed
    Score: 0.365
  44. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015 May; 19(2):361-79.
    View in: PubMed
    Score: 0.359
  45. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015 Feb; 12(2):65-6.
    View in: PubMed
    Score: 0.355
  46. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26; 392(24):2413-2424.
    View in: PubMed
    Score: 0.182
  47. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 05; 392(21):2089-2099.
    View in: PubMed
    Score: 0.181
  48. Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.
    View in: PubMed
    Score: 0.175
  49. Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch. Hepatology. 2024 Jul 01; 80(1):E13-E14.
    View in: PubMed
    Score: 0.168
  50. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.167
  51. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol. 2024 01; 9(1):83-91.
    View in: PubMed
    Score: 0.165
  52. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. Hepatol Commun. 2024 01 01; 8(1).
    View in: PubMed
    Score: 0.165
  53. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024 03; 80(3):419-430.
    View in: PubMed
    Score: 0.164
  54. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 03 01; 79(3):674-689.
    View in: PubMed
    Score: 0.162
  55. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease". Hepatology. 2024 01 01; 79(1):E5-E6.
    View in: PubMed
    Score: 0.162
  56. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. 2023 Nov; 79(5):1110-1120.
    View in: PubMed
    Score: 0.161
  57. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023 09; 79(3):618-634.
    View in: PubMed
    Score: 0.159
  58. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023 10; 79(4):1015-1024.
    View in: PubMed
    Score: 0.159
  59. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
    View in: PubMed
    Score: 0.158
  60. Research Priorities for Precision Medicine in NAFLD. Clin Liver Dis. 2023 05; 27(2):535-551.
    View in: PubMed
    Score: 0.156
  61. The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States. J Gastrointestin Liver Dis. 2022 09 15; 31(3):317-322.
    View in: PubMed
    Score: 0.151
  62. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
    View in: PubMed
    Score: 0.147
  63. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022 07; 7(7):603-616.
    View in: PubMed
    Score: 0.146
  64. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041.
    View in: PubMed
    Score: 0.145
  65. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022 01; 55(2):234-243.
    View in: PubMed
    Score: 0.143
  66. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 01; 19(1):60-78.
    View in: PubMed
    Score: 0.142
  67. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring). 2021 09; 29(9):1401-1412.
    View in: PubMed
    Score: 0.140
  68. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 09; 44(9):2162-2172.
    View in: PubMed
    Score: 0.140
  69. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
    View in: PubMed
    Score: 0.140
  70. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
    View in: PubMed
    Score: 0.140
  71. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12.
    View in: PubMed
    Score: 0.139
  72. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 05; 73(5):2028-2038.
    View in: PubMed
    Score: 0.137
  73. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021 03; 73(3):1194-1198.
    View in: PubMed
    Score: 0.135
  74. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol. 2021 04; 74(4):972-974.
    View in: PubMed
    Score: 0.134
  75. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
    View in: PubMed
    Score: 0.131
  76. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71.
    View in: PubMed
    Score: 0.130
  77. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526.
    View in: PubMed
    Score: 0.130
  78. Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. J Am Heart Assoc. 2020 02 18; 9(4):e014279.
    View in: PubMed
    Score: 0.126
  79. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5.
    View in: PubMed
    Score: 0.125
  80. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 12 14; 394(10215):2184-2196.
    View in: PubMed
    Score: 0.125
  81. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.124
  82. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019 11; 70(5):1841-1855.
    View in: PubMed
    Score: 0.124
  83. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. J Gen Intern Med. 2019 12; 34(12):2772-2778.
    View in: PubMed
    Score: 0.123
  84. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci. 2019 12; 64(12):3413-3430.
    View in: PubMed
    Score: 0.121
  85. Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplant Proc. 2019 Jul - Aug; 51(6):1895-1901.
    View in: PubMed
    Score: 0.121
  86. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 09; 84:105803.
    View in: PubMed
    Score: 0.121
  87. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2019 05; 114(5):758-763.
    View in: PubMed
    Score: 0.120
  88. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int. 2019 05; 39(5):933-940.
    View in: PubMed
    Score: 0.117
  89. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018 10; 48(7):696-703.
    View in: PubMed
    Score: 0.114
  90. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 07; 24(7):908-922.
    View in: PubMed
    Score: 0.113
  91. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371.
    View in: PubMed
    Score: 0.113
  92. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.113
  93. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018 06; 47(12):1639-1651.
    View in: PubMed
    Score: 0.112
  94. Twenty-five-year trajectories of insulin resistance and pancreatic ß-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int. 2018 11; 38(11):2069-2081.
    View in: PubMed
    Score: 0.111
  95. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018 03 24; 391(10126):1174-1185.
    View in: PubMed
    Score: 0.110
  96. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714.
    View in: PubMed
    Score: 0.107
  97. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.107
  98. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 05; 112(5):755-762.
    View in: PubMed
    Score: 0.103
  99. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 12 17; 1:15080.
    View in: PubMed
    Score: 0.095
  100. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015 Sep; 62(3):773-83.
    View in: PubMed
    Score: 0.092
  101. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50.
    View in: PubMed
    Score: 0.076
  102. A myriad of pathways to NASH. Clin Liver Dis. 2012 Aug; 16(3):525-48.
    View in: PubMed
    Score: 0.074
  103. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012 Mar; 112(3):401-9.
    View in: PubMed
    Score: 0.073
  104. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20.
    View in: PubMed
    Score: 0.071
  105. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology. 2011 Nov; 54(5):1600-9.
    View in: PubMed
    Score: 0.070
  106. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
    View in: PubMed
    Score: 0.070
  107. Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers. Liver Int. 2024 Aug; 44(8):1990-2001.
    View in: PubMed
    Score: 0.042
  108. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.